Balyasny Asset Management
RCUS icon

Balyasny Asset Management’s Arcus Biosciences RCUS Stock Holding History

Balyasny Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,232,500
Closed -$29.4M – 3418
2025
Q4 		$29.4M Sell
1,232,500
-540,000
-30% -$11M 0.04% 544
2025
Q3 		$24.1M Buy
1,772,500
+65,000
+4% +$676K 0.03% 632
2025
Q2 		$13.9M Buy
+1,707,500
New +$14.6M 0.02% 813

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's RCUS Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 22,845 shares worth $704K. The stake represents ﹤0.01% of the portfolio and ranks #2376 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in RCUS as recently as Q4 2025.

Balyasny Asset Management first reported a position in RCUS in Q1 2020 and has held it in 17 quarters since. The position peaked at $37.9M in Q2 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Balyasny Asset Management held 22,845 shares of Arcus Biosciences worth $704K as of Q2 2026.
  • Arcus Biosciences was a new Balyasny Asset Management position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2376 holding.
  • Balyasny Asset Management first reported a position in Arcus Biosciences in Q1 2020 and has held it in 17 quarters since.
  • Balyasny Asset Management's Arcus Biosciences position peaked at $37.9M in Q2 2023.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.